Lincoln Pharmaceuticals Ltd (LINCOLN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Lincoln Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 29 Oct 2026, 6:00 pm
Un-Audited Financial Results For the Quarter and Half year Ended on September 30 ,2026.
Financial Result · 29 Oct 2026, 5:57 pm
Un-Audited Financial Results For the Quarter and Half Year ended on September 30, 2026.
Outcome · 29 Oct 2026, 5:51 pm
Lincoln Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 19,135 (+17.1% YoY | +7.9% QoQ) ■ EBITDA: 2,369 (-6.8% YoY | -13.7% QoQ) ■ EBITDA Margin (%): 12.4 (-319 bps YoY | -309 bps QoQ) ■ PAT: 2,043 (+2.2% YoY | -43.6% QoQ) ■ EPS (INR): 10.2 (+2.2% YoY | -43.6% QoQ)
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 29 Oct 2026, 5:30 am
LINCOLN PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 29 Oct 2026, 5:30 am
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Intimation · 29 Oct 2026, 5:30 am
Lincoln Pharmaceuticals Schedules Board Meeting on 29th Oct'26 for Q2 Results Lincoln Pharmaceuticals Limited has scheduled a Board of Directors meeting on 29th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed since 1st Oct'26 and will reopen 48 hours after the public dissemination of the financial results.
Change in Senior Management.
Change in Management · 17 Oct 2026, 10:56 pm
Lincoln Pharmaceuticals Senior Management Personnel Resignation Lincoln Pharmaceuticals Ltd has announced the resignation of Mr. Pradeep Kumar Yadav from his position as Senior General Manager – Quality Assurance, designated as Senior Management Personnel. The resignation, cited due to personal reasons, became effective after the close of business hours on 17th Oct'26.
with reference to the above, Please find enclosed herewith the Minutes of 32nd Annual General Meeting of the Company.
Annual General Meeting · 16 Oct 2026, 11:17 pm
Submission of E-Voting Results of 32nd AGM along with the scrutinizer report as per Regulation 44 of SEBI (LODR) Regulation, 2015.
Annual General Meeting · 03 Oct 2026, 10:24 pm
Submission of Proceedings of the 32nd Annual General Meeting of the Company held today.
Annual General Meeting · 30 Sept 2026, 10:02 pm
We wish to informed you that Mr. Pradeep Kumar Yadav has been appointed as " Senior General Manager- Quality Assurance (Senior Management Personnel) of the Company w.e.f 24-09-2026.
Change in Management · 24 Sept 2026, 7:52 pm
Lincoln Pharmaceuticals Appoints Pradeep Kumar Yadav as Senior General Manager QA Lincoln Pharmaceuticals Ltd appointed Pradeep Kumar Yadav as Senior General Manager-Quality Assurance, designated as Senior Management Personnel, effective 24th Sep'26. Based at the Khatraj manufacturing facility, Yadav brings over 20 years of pharmaceutical industry experience, specializing in Quality Management Systems, audit compliance, validation, IPQA, and vendor management. His background includes direct involvement in regulatory inspections conducted by international agencies, including the USFDA, MHRA, TGA, ANVISA, WHO Geneva, and SAHPRA. His appointment includes a six-month probation period and a two-year service bond.
Change in Senior Management.
Change in Management · 24 Sept 2026, 7:38 pm
Lincoln Pharmaceuticals Announces Resignation of Senior Management Personnel Manoj Rai Lincoln Pharmaceuticals Ltd informed exchanges under SEBI LODR Regulation 30 that Manoj Rai, Senior General Manager – QA (Head QA) and designated Senior Management Personnel, has resigned due to personal reasons to pursue outside professional opportunities. His cessation took effect from the close of business hours on 24th Sep'26 following the completion of his transition period. The company has initiated steps to arrange a replacement for the quality assurance leadership role.
Intimation regarding dispatch of physical communication to the Shareholders who have not registered their email address.
Annual Report · 06 Sept 2026, 12:31 am
Pursuant to Regulation 34(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the SEBI Listing Regulations"), we are submitting ....
Others (Uncategorized) · 06 Sept 2026, 12:19 am
32nd Annual General Meeting ("AGM") of the Members of the Company will be held on Wednesday, 30th September, 2026 at 11:00 A.M. (IST) through Video Conferencing ("VC")/Other Audio-Visual ....
Annual General Meeting · 06 Sept 2026, 12:03 am
The intimation of Book Closure and Record date is as enclosed.
Dividend · 29 Aug 2026, 8:45 pm
Lincoln Pharmaceuticals Announces FY26 Final Dividend and Record Date Lincoln Pharmaceuticals (NSE: LINCOLN, BSE: 531633) has declared a final dividend of ₹1.80 per equity share (18%) for the financial year 2025-26, subject to shareholder approval. The record date to determine eligibility for the dividend is Fri, 11 Sep'26. The book closure period is scheduled from Sat, 12 Sep'26 to Wed, 30 Sep'26. The dividend proposal will be considered at the 32nd Annual General Meeting (AGM) scheduled for Wed, 30 Sep'26.
Un-Audited Financial Results For Quarter Ended on 30 June, 2026.
Financial Result · 13 Aug 2026, 5:16 pm
Lincoln Pharma Q1FY27: Net Profit Surges 30.9% YoY on Strong Revenue Growth Lincoln Pharmaceuticals reported robust Q1 FY27 results with consolidated net profit rising 30.9% YoY to ₹36.23 crore. Total income grew 19.02% YoY to ₹201.55 crore for the quarter ended 30-Jun'26. EBITDA increased 32.29% YoY to ₹51.70 crore. QoQ, net profit was up 211.5% from ₹11.63 crore, while revenue grew 10.1% from ₹183.08 crore. The company is targeting ₹1,000 crore in revenue over the next three years, driven by strong performance and global expansion into regulated markets. Basic EPS for the quarter was ₹18.09.
Un-Audited Financial Results of the Company For the Quarter Ended June 30, 2026.
Outcome · 13 Aug 2026, 5:07 pm
Lincoln Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 17,728 (+15.1% YoY | -5.3% QoQ) ■ EBITDA: 5,589 (+134.8% YoY | +124.9% QoQ) ■ EBITDA Margin (%): 31.5 (+1608 bps YoY | +1826 bps QoQ) ■ PAT: 3,623 (+30.9% YoY | +211.4% QoQ) ■ EPS (INR): 18.1 (+30.9% YoY | +211.4% QoQ)
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Lincoln Pharmaceuticals ....
Intimation · 13 Aug 2026, 5:30 am
Lincoln Pharma Board to Approve Q1 FY27 Results on 13 Aug'26 Lincoln Pharmaceuticals' Board of Directors will meet on 13 Aug'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 Jun'26. In accordance with SEBI regulations, the trading window for the company's securities has been closed since 01 Jul'26 and will reopen 48 hours after the financial results are publicly announced. The company's Scrip Codes are LINCOLN (NSE) and 531633 (BSE).
Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity share of face value Rs. 10/- each for the financial year ended March 31, 2026 subject to approval of the members at the ensuing ....
Dividend · 28 May 2026, 10:51 pm
Lincoln Pharma Q4FY26 Results: Modest PAT Growth and Dividend Declared Lincoln Pharmaceuticals reported Q4FY26 standalone net profit of ₹11.63 crore, up 0.5% YoY, on revenue of ₹187.28 crore, up 11.4% YoY. For FY26, net profit grew 6.7% YoY to ₹87.89 crore while revenue increased 7.7% YoY to ₹671.03 crore. The board has recommended a final dividend of ₹1.80 per share (18%) for the year ended 31 Mar'26, subject to shareholder approval. Full-year FY26 EPS stood at ₹43.88 versus ₹41.11 in FY25. The results are based on standalone audited financials.
Audited Financial Results for the Quarter and Year ended March 31, 2026.
Financial Result · 28 May 2026, 10:46 pm
Lincoln Pharma FY26: Modest Profit Growth and Dividend Declared Lincoln Pharmaceuticals reported Q4FY26 standalone net profit of ₹11.63 Cr, up 0.5% YoY, on revenue of ₹187.28 Cr, up 11.4% YoY. For FY26, net profit grew 6.7% YoY to ₹87.89 Cr, with revenue up 7.7% to ₹671.03 Cr. The board recommended a dividend of ₹1.80 per share (18%) for FY26, subject to shareholder approval. Consolidated revenue for FY26 was ₹704.48 Cr (+9.1% YoY) with net profit at ₹87.89 Cr (+6.7% YoY). FII holding increased to 5.20% as of 31 Mar'26.
Outcome of Board Meeting for Audited Financial Results for the Quarter and Year Ended 31st March, 2026.
Outcome · 28 May 2026, 10:39 pm
Lincoln Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 18,728 (+11.4% YoY | +12.6% QoQ) ■ EBITDA: 2,486 (-7.0% YoY | +5.3% QoQ) ■ EBITDA Margin (%): 13.3 (-262 bps YoY | -91 bps QoQ) ■ PAT: 1,163 (+0.5% YoY | -59.3% QoQ) ■ EPS (INR): 5.81 (+0.5% YoY | -59.3% QoQ)
Meeting of the Board of Directors is scheduled to be held on May 28, 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares ....
Dividend · 18 May 2026, 8:12 pm
Lincoln Pharma Board Meeting Set for May 28 to Discuss Q4 Results, Dividend Lincoln Pharmaceuticals (NSE: LINCOLN) has scheduled a Board of Directors meeting for Thu, 28 May'26. The agenda includes the consideration and approval of audited standalone and consolidated financial results for the quarter and year ended 31 Mar'26. The board will also consider a recommendation for a dividend on equity shares. In connection with this, the trading window for company securities has been closed since 01 Apr'26 and will reopen 48 hours after the results are made public.
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Audited (standalone ....
Intimation · 28 May 2026, 5:30 am
Lincoln Pharma Board to Review Q4 & FY26 Results, Consider Dividend on May 28 Lincoln Pharmaceuticals' Board of Directors will meet on 28 May'26 to approve audited standalone and consolidated financial results for the quarter and year ended 31 Mar'26. The agenda also includes consideration of a dividend recommendation. In compliance with SEBI regulations, the trading window for company securities has been closed since 01 Apr'26 and will reopen 48 hours after the financial results are publicly announced. This meeting is a key event for investors awaiting performance updates and potential dividend payouts.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 05 May 2026, 10:22 pm
Lincoln Pharma Not Classified as a Large Corporate for FY26-27 Lincoln Pharmaceuticals Ltd. informed exchanges on 05 May'26 that it does not qualify as a Large Corporate (LC) as of 31 Mar'26, according to SEBI's framework. Consequently, the mandatory borrowing requirements under the LC regulations for the two-year block period of FY 2026 and FY 2027 are not applicable to the company. This disclosure confirms its exemption from the specified fundraising obligations for the period.